Viridian Therapeutics, Inc. VRDN Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s stock issuance proceeds?
- Viridian Therapeutics, Inc. (VRDN) reported stock issuance proceeds of $0 in Q1 2026.
- How has Viridian Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Viridian Therapeutics, Inc.'s stock issuance proceeds decreased by 100.0% year-over-year, from $4.94M to $0.
- What is the long-term trend for Viridian Therapeutics, Inc.'s stock issuance proceeds?
- Over 3 years (2021 to 2025), Viridian Therapeutics, Inc.'s stock issuance proceeds has grown at a -17.1% compound annual growth rate (CAGR), from $114.24M to $65.03M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.